Trials / Completed
CompletedNCT02503774
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 192 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 101 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Participants with Select Advanced Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oleclumab | Participants will receive IV infusion of oleclumab as stated in arms' description. |
| DRUG | Durvalumab | Participants will receive IV infusion of durvalumab as stated in arms' description. |
Timeline
- Start date
- 2015-07-24
- Primary completion
- 2021-01-22
- Completion
- 2023-03-07
- First posted
- 2015-07-21
- Last updated
- 2023-07-11
Locations
18 sites across 3 countries: United States, Australia, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02503774. Inclusion in this directory is not an endorsement.